Does the media refer more to AVXL or CRDF?

In the previous week, Cardiff Oncology had 7 more articles in the media than Anavex Life Sciences. MarketBeat recorded 9 mentions for Cardiff Oncology and 2 mentions for Anavex Life Sciences. Cardiff Oncology's average media sentiment score of 0.82 beat Anavex Life Sciences' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRDF or IRD?

In the previous week, Cardiff Oncology had 7 more articles in the media than Opus Genetics. MarketBeat recorded 9 mentions for Cardiff Oncology and 2 mentions for Opus Genetics. Cardiff Oncology's average media sentiment score of 0.82 beat Opus Genetics' score of 0.30 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SION or CRDF?

In the previous week, Cardiff Oncology had 1 more articles in the media than Sionna Therapeutics. MarketBeat recorded 9 mentions for Cardiff Oncology and 8 mentions for Sionna Therapeutics. Cardiff Oncology's average media sentiment score of 0.82 beat Sionna Therapeutics' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cardiff Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MYGN or CRDF?

In the previous week, Cardiff Oncology had 7 more articles in the media than Myriad Genetics. MarketBeat recorded 9 mentions for Cardiff Oncology and 2 mentions for Myriad Genetics. Cardiff Oncology's average media sentiment score of 0.82 beat Myriad Genetics' score of 0.30 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cardiff Oncology (CRDF) Competitors

$1.00 +0.12 (+14.19%)

As of 12:44 PM Eastern

Compare

CRDF vs. AVXL, IRD, SION, TRDA, and MYGN

Should you buy Cardiff Oncology stock or one of its competitors? Cardiff Oncology's main competitors and comparable companies include Anavex Life Sciences (AVXL), Opus Genetics (IRD), Sionna Therapeutics (SION), Entrada Therapeutics (TRDA), and Myriad Genetics (MYGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cardiff Oncology compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, Cardiff Oncology had 7 more articles in the media than Anavex Life Sciences. MarketBeat recorded 9 mentions for Cardiff Oncology and 2 mentions for Anavex Life Sciences. Cardiff Oncology's average media sentiment score of 0.82 beat Anavex Life Sciences' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiff Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiff Oncology has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.39	N/A
Cardiff Oncology	$508K	153.91	-$45.85M	-$0.60	N/A

Anavex Life Sciences currently has a consensus target price of $21.33, suggesting a potential upside of 574.04%. Cardiff Oncology has a consensus target price of $7.50, suggesting a potential upside of 646.27%. Given Cardiff Oncology's higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Anavex Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Anavex Life Sciences has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. Anavex Life Sciences' return on equity of -32.73% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-32.73%	-30.15%
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 8.5% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Anavex Life Sciences has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Summary

Anavex Life Sciences beats Cardiff Oncology on 8 of the 15 factors compared between the two stocks.

How does Cardiff Oncology compare to Opus Genetics?

Cardiff Oncology (NASDAQ:CRDF) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Cardiff Oncology has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Opus Genetics has a net margin of -1,091.82% compared to Cardiff Oncology's net margin of -7,885.43%. Cardiff Oncology's return on equity of -103.10% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Cardiff Oncology currently has a consensus target price of $7.50, suggesting a potential upside of 646.27%. Opus Genetics has a consensus target price of $10.69, suggesting a potential upside of 156.41%. Given Cardiff Oncology's higher probable upside, equities research analysts plainly believe Cardiff Oncology is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

Cardiff Oncology has higher earnings, but lower revenue than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$508K	153.91	-$45.85M	-$0.60	N/A
Opus Genetics	$14.20M	24.27	-$49.59M	-$1.35	N/A

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Cardiff Oncology had 7 more articles in the media than Opus Genetics. MarketBeat recorded 9 mentions for Cardiff Oncology and 2 mentions for Opus Genetics. Cardiff Oncology's average media sentiment score of 0.82 beat Opus Genetics' score of 0.30 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cardiff Oncology beats Opus Genetics on 11 of the 17 factors compared between the two stocks.

How does Cardiff Oncology compare to Sionna Therapeutics?

Sionna Therapeutics (NASDAQ:SION) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Sionna Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Sionna Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. Sionna Therapeutics' return on equity of -32.94% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-32.94%	-31.08%
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

Cardiff Oncology has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A
Cardiff Oncology	$508K	153.91	-$45.85M	-$0.60	N/A

Sionna Therapeutics currently has a consensus price target of $42.22, indicating a potential upside of 687.88%. Cardiff Oncology has a consensus price target of $7.50, indicating a potential upside of 646.27%. Given Sionna Therapeutics' higher possible upside, analysts plainly believe Sionna Therapeutics is more favorable than Cardiff Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

16.3% of Cardiff Oncology shares are owned by institutional investors. 5.1% of Sionna Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Cardiff Oncology had 1 more articles in the media than Sionna Therapeutics. MarketBeat recorded 9 mentions for Cardiff Oncology and 8 mentions for Sionna Therapeutics. Cardiff Oncology's average media sentiment score of 0.82 beat Sionna Therapeutics' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cardiff Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cardiff Oncology beats Sionna Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Cardiff Oncology compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, Cardiff Oncology had 9 more articles in the media than Entrada Therapeutics. MarketBeat recorded 9 mentions for Cardiff Oncology and 0 mentions for Entrada Therapeutics. Cardiff Oncology's average media sentiment score of 0.82 beat Entrada Therapeutics' score of 0.00 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Entrada Therapeutics	Neutral
Cardiff Oncology	Positive

86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Entrada Therapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Entrada Therapeutics has a net margin of -3,537.73% compared to Cardiff Oncology's net margin of -7,885.43%. Entrada Therapeutics' return on equity of -57.61% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

Cardiff Oncology has lower revenue, but higher earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	11.24	-$143.75M	-$3.96	N/A
Cardiff Oncology	$508K	153.91	-$45.85M	-$0.60	N/A

Entrada Therapeutics presently has a consensus target price of $17.75, suggesting a potential upside of 141.99%. Cardiff Oncology has a consensus target price of $7.50, suggesting a potential upside of 646.27%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Entrada Therapeutics and Cardiff Oncology tied by winning 8 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Myriad Genetics?

Myriad Genetics (NASDAQ:MYGN) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cardiff Oncology has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.36	-$365.90M	-$1.19	N/A
Cardiff Oncology	$508K	153.91	-$45.85M	-$0.60	N/A

Myriad Genetics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Myriad Genetics has a net margin of -13.96% compared to Cardiff Oncology's net margin of -7,885.43%. Myriad Genetics' return on equity of -16.09% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%

Myriad Genetics currently has a consensus target price of $4.90, suggesting a potential upside of 59.87%. Cardiff Oncology has a consensus target price of $7.50, suggesting a potential upside of 646.27%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Cardiff Oncology had 7 more articles in the media than Myriad Genetics. MarketBeat recorded 9 mentions for Cardiff Oncology and 2 mentions for Myriad Genetics. Cardiff Oncology's average media sentiment score of 0.82 beat Myriad Genetics' score of 0.30 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiff Oncology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cardiff Oncology beats Myriad Genetics on 10 of the 16 factors compared between the two stocks.

Get Cardiff Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDF vs. The Competition

Export

Metric	Cardiff Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$78.18M	$3.98B	$7.28B	$12.76B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-1.67	11.63	271.38	24.12
Price / Sales	153.91	1,324.23	612.61	78.45
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	1.50	17.22	11.17	6.40
Net Income	-$45.85M	-$22.72M	$3.46B	$348.28M
7 Day Performance	11.14%	2.91%	2.07%	1.29%
1 Month Performance	21.54%	9.83%	7.44%	5.47%
1 Year Performance	-56.68%	54.58%	24.72%	16.27%

Cardiff Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDF Cardiff Oncology	3.4404 of 5 stars	$1.01 +14.2%	$7.50 +646.3%	-62.1%	$78.18M	$508K	N/A	20	Gap Up
AVXL Anavex Life Sciences	1.1564 of 5 stars	$3.21 -0.3%	$21.33 +564.6%	-66.0%	$298.48M	N/A	N/A	40
IRD Opus Genetics	2.5621 of 5 stars	$3.65 +1.1%	$10.69 +192.9%	+252.2%	$298.36M	$14.20M	N/A	14
SION Sionna Therapeutics	3.2667 of 5 stars	$5.91 -8.5%	$42.22 +614.4%	-78.3%	$292.07M	N/A	N/A	35
TRDA Entrada Therapeutics	2.5123 of 5 stars	$7.32 -1.9%	$17.75 +142.5%	+23.3%	$290.47M	$25.42M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDF) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiff Oncology (CRDF) Competitors

CRDF vs. AVXL, IRD, SION, TRDA, and MYGN

How does Cardiff Oncology compare to Anavex Life Sciences?

Summary

How does Cardiff Oncology compare to Opus Genetics?

Summary

How does Cardiff Oncology compare to Sionna Therapeutics?

Summary

How does Cardiff Oncology compare to Entrada Therapeutics?

Summary

How does Cardiff Oncology compare to Myriad Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiff Oncology (CRDF) Competitors

CRDF vs. AVXL, IRD, SION, TRDA, and MYGN

How does Cardiff Oncology compare to Anavex Life Sciences?

Does the media refer more to AVXL or CRDF?

Which has better earnings & valuation, AVXL or CRDF?

Do analysts recommend AVXL or CRDF?

Is AVXL or CRDF more profitable?

Do institutionals & insiders have more ownership in AVXL or CRDF?

Which has more volatility and risk, AVXL or CRDF?

Summary

How does Cardiff Oncology compare to Opus Genetics?

Which has more volatility & risk, CRDF or IRD?

Is CRDF or IRD more profitable?

Do analysts recommend CRDF or IRD?

Which has stronger earnings & valuation, CRDF or IRD?

Do insiders & institutionals hold more shares of CRDF or IRD?

Does the media prefer CRDF or IRD?

Summary

How does Cardiff Oncology compare to Sionna Therapeutics?

Which has more volatility and risk, SION or CRDF?

Is SION or CRDF more profitable?

Which has preferable earnings & valuation, SION or CRDF?

Do analysts rate SION or CRDF?

Do insiders & institutionals have more ownership in SION or CRDF?

Does the media refer more to SION or CRDF?

Summary

How does Cardiff Oncology compare to Entrada Therapeutics?

Does the media refer more to TRDA or CRDF?

Do insiders and institutionals believe in TRDA or CRDF?

Which has more volatility & risk, TRDA or CRDF?

Is TRDA or CRDF more profitable?

Which has better valuation and earnings, TRDA or CRDF?

Do analysts rate TRDA or CRDF?

Summary

How does Cardiff Oncology compare to Myriad Genetics?

Do institutionals & insiders hold more shares of MYGN or CRDF?

Which has higher earnings & valuation, MYGN or CRDF?

Which has more volatility and risk, MYGN or CRDF?

Is MYGN or CRDF more profitable?

Do analysts prefer MYGN or CRDF?

Does the media favor MYGN or CRDF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF vs. The Competition

Cardiff Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools